Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+ T cells

Nature Medicine

Volumn 12, Issue 6, 2006, Pages 627-635

  Ochi, Hirofumi ^a   Abraham, Michal ^a   Ishikawa, Hiroki ^a   Frenkel, Dan ^a   Yang, Kaiyong ^a   Basso, Alexandre S ^a   Wu, Henry ^a   Chen, Mei Ling ^a   Gandhi, Roopali ^a   Miller, Ariel ^b   Maron, Ruth ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; LATENCY ASSOCIATED PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL ACTIVITY; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL SURFACE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG UPTAKE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; MOLECULAR DYNAMICS; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CRICETINAE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDES; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33744990181     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1408     Document Type: Article

References (42)

1. Herold, K.C. et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41, 385-391 (1992).
2. Chatenoud, L., Thervet, E., Primo, J. & Bach, J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91, 123-127 (1994).
3. Chatenoud, L., Primo, J. & Bach, J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947-2954 (1997).
4. Mottram, P.L., Murray-Segal, L.J., Han, W., Maguire, J. & Stein-Oakley, A.N. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl. Immunol. 10, 63-72 (2002).
5. von Herrath, M.G., Coon, B., Wolfe, T. & Chatenoud, L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 168, 933-941 (2002).
6. Belghith, M. et al. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med.9, 1202-1208 (2003).
7. Tran, G.T. et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int. Immunol. 13, 1109-1120 (2001).
8. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174, 4525-4534 (2005).
9. Herold, K.C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
10. Herold, K.C. et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111, 409-418 (2003).
11. Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
12. + Tregs. J. Clin. Invest. 115, 2904-2913 (2005).
13. Herold, K.C. et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769 (2005).
14. Utset, T.O. et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29, 1907-1913 (2002).
15. Chatenoud, L. et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 12, 979-982 (1982).
16. Chatenoud, L. et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137, 830-838 (1986).
17. Chatenoud, L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3, 123-132 (2003).
18. Faria, A.M. & Weiner, H.L. Oral tolerance. Immunol. Rev. 206, 232-259 (2005).
19. Zhang, Z.J., Davidson, L., Eisenbarth, G. & Weiner, H.L. Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88, 10252-10256 (1991).
20. Maron, R. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106, 1708-1715 (2002).
21. + T cells. J. Immunol. 171, 6549-6555 (2003).
22. Miller, A., Lider, O., Roberts, A.B., Sporn, M.B. & Weiner, H.L. Suppressor T-cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigen-specific triggering. Proc. Natl. Acad. Sci. USA 89, 421-425 (1992).
23. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A. & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
24. +) regulatory T cells by oral antigen administration. J. Immunol. 167, 4245-4253 (2001).
25. + T lymphocytes. J. Immunol. 142, 748-752 (1989).
26. high-induced colitis by a TGF-β-dependent mechanism. J. Immunol. 170, 2516-2522 (2003).
27. +) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644 (2001).
28. Nakamura, K. et al. TGF-β 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842 (2004).
29. Inobe, J. et al. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28, 2780-2790 (1998).
30. Slavin, A.J., Maron, R. & Weiner, H.L. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int. Immunol. 13, 825-833 (2001).
31. Sayegh, M.H., Khoury, S.J., Hancock, W.W., Weiner, H.L. & Carpenter, C.B. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc. Natl. Acad. Sci. USA 89, 7762-7766 (1992).
32. Miller, A., al-Sabbagh, A., Santos, L.M., Das, M.P. & Weiner, H.L. Epitopes of myelin basic protein that trigger TGF-β release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 151, 7307-7315 (1993).
33. Maron, R., Melican, N.S. & Weiner, H.L. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J. Autoimmun. 12, 251-258 (1999).
34. Wesselborg, S., Janssen, O. & Kabelitz, D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150, 4338-4345 (1993).
35. Friedman, A. & Weiner, H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA 91, 6688-6692 (1994).
36. Chen, Y., Inobe, J., Marks, R., Gonnella, P., Kuchroo, V.J. & Weiner, H.L. Peripheral deletion of antigen-reactive T-cells in oral tolerance. Nature 376, 177-180 (1995).
37. + T cells. J. Immunol. 170, 2427-2434 (2003).
38. Leitenberg, D. & Bottomly, K. Regulation of naive T cell differentiation by varying the potency of TCR signal transduction. Semin. Immunol. 11, 283-292 (1999).
39. Khoury, S.J., Hancock, W.W. & Weiner, H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176, 1355-1364 (1992).
40. + T cells. Int. Immunol. 18, 495-503 (2006).
41. Weinshenker, B.G., Bass, B., Karlik, S., Ebers, G.C. & Rice, G.P. An open trial of OKT3 in patients with multiple sclerosis. Neurology 41, 1047-1052 (1991).
42. Hafler, D.A., Ritz, J., Schlossman, S.F. & Weiner, H.L. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J. Immunol. 141, 131-138 (1988).